WILMINGTON, Del.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU庐 (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the pivotal <a ...
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to ...
SAN FRANCISCO--(BUSINESS WIRE)--Oct 23, 2023--<a ...
DOVER, Del. & LOUISVILLE, Ky.--(BUSINESS WIRE)--Oct 23, 2023--The Division of Substance Abuse and Mental Health (DSAMH) of Delaware has selected Bamboo Health to implement its <a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2023--<a ...